Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. - Wikidata - awgldk - TriplyDB

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.

http://www.wikidata.org/entity/Q37725870

about

Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab Interleukin-6: an emerging regulator of pathological pain The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives Challenges and opportunities in designing clinical trials for neuromyelitis optica Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor.The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations.Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.B lymphocytes in neuromyelitis optica Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder.Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.IL4 induces IL6-producing M2 macrophages associated to inhibition of neuroinflammation in vitro and in vivo Cytokine Therapies in Neurological Disease.Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro Neuromyelitis optica spectrum disorders.Therapeutic uses of anti-interleukin-6 receptor antibody.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.Atypical Optic Neuritis.The role and therapeutic targeting of IL-6 in rheumatoid arthritis.Therapeutic options in neuromyelitis optica spectrum disorders.Tocilizumab for treating juvenile idiopathic arthritis.Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.Neuromyelitis Optica (Devic's Syndrome): an Appraisal.Efficiency of antibody therapy in demyelinating diseases.Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.Cytokines and matrix metalloproteinases in the cerebrospinal fluid of patients with acute transverse myelitis: an outcome analysis.Interleukin-6 Blockade as Rescue Therapy in Autoimmune Encephalitis.Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice.Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica.Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.Treatment strategies for autoimmune encephalitis.Tocilizumab reduced production of systemic sclerosis-related autoantibodies and anti-cyclic citrullinated protein antibodies in two patients with overlapping systemic sclerosis and rheumatoid arthritis.Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Interleukin-6, S-Nitrosothiols, and Neurodegeneration in Different Central Nervous System Demyelinating Disorders: Is There a Relationship?

P2860

Q21146701-83B9AD4D-47B0-4CF6-BC2F-DE8050B49B7E Q26748646-D6FA7DD2-7C7A-4BFA-ADA2-0C123863A4CA Q26767391-9C5CE743-696D-4AEE-AA32-7D04BDA0E9AB Q26999708-B5006624-060E-4281-AB8D-787C0FBE7C3D Q30975717-D3F1505D-3A57-40B7-ADDA-11B4DE7B2D10 Q33737913-F51A28F9-4842-4B27-933C-D10F5FD53CDB Q34459965-AAB09218-5266-4809-B945-B9FB46915068 Q34545836-599AC87F-7259-4B02-BA5D-7BC21CE93420 Q35591039-BBFFE859-49F1-4E89-BA09-FC3CC1159098 Q36118869-7FFAFE39-25A3-4074-B7D0-AADE55745FCA Q36484383-E8E663D3-6753-4391-BD5A-9E1DA172D7AB Q36484394-5AE48AA2-FB3D-4488-A0BA-FCE33111D6AA Q36547012-030D6867-F64B-415C-99BD-258E8F4AE504 Q36727762-F2C3AD9E-0AEC-4F93-89AD-92FEAAE81C19 Q36976119-0B868E01-9D60-4A80-9A07-50518A3DFF7D Q37136498-24E9C27C-5D73-444E-BDFA-7F0B5B06A22A Q37520888-E410438F-9010-4227-89E8-54BCACA5C0E4 Q38229823-CECD9BAB-C349-4EBE-8A56-E838FD349DD3 Q38241714-97C91515-158E-4583-A52C-826E0A34FFCF Q38286209-89F3FCB2-514C-4518-BB96-24BBE532783B Q38409715-B9C3649E-D279-42F2-941C-756280F6AA5C Q38607165-A33DCD43-2859-4670-8565-52BA48BAC06A Q38685086-F41FDCCA-72D5-400E-BE9E-1B496F8058FA Q38721559-EF06224F-C4BA-46C7-AD73-1DC96B93897A Q38723988-BB2374C0-C833-4693-89B5-2C82F0888F97 Q38816869-BABC788D-AF12-49A6-BD16-C0989D6BB8E9 Q38831970-1A715CE5-BB45-44F1-B1AF-7876BE3AA0F8 Q38893206-87F1356E-042D-4F64-9B8F-11ACF34C55C5 Q40045794-4F7235D3-6AB6-49E3-AC88-67E883ECB2F9 Q40715894-93BC96A6-2374-4704-AFE5-EE4CA673367C Q41095945-05462185-432F-4EE2-8A7F-DF0995C3D8FA Q42379836-F91CE0E1-B4ED-4BD4-BC5B-AF6F3308C2A4 Q42609904-B612C88F-B4AB-4CF3-A21A-9F0C22B1A49F Q47192132-1AF7D35E-7027-4627-BF18-EE233B1D3F7F Q48949337-C3804E93-1D8F-4C02-A147-D9B2DFDF9410 Q49213573-581E5D52-A106-46FE-BFE3-AEB3087DFB84 Q51015817-82597E0D-F533-4D43-A026-979B68E808DF Q53813269-F96303EE-DF3D-4D91-80B3-C1ADF221A397 Q55052878-33DBE41A-374E-4B3A-9BFA-AE620BEFD546 Q55434832-4F59F248-F3C6-4648-9485-23F89D384857

P2860

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.

http://www.wikidata.org/entity/Q37725870

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy of the anti-IL-6 rece ...... yelitis optica: a pilot study.

@en

Efficacy of the anti-IL-6 rece ...... yelitis optica: a pilot study.

@nl

type

label

Efficacy of the anti-IL-6 rece ...... yelitis optica: a pilot study.

@en

Efficacy of the anti-IL-6 rece ...... yelitis optica: a pilot study.

@nl

prefLabel

Efficacy of the anti-IL-6 rece ...... yelitis optica: a pilot study.

@en

Efficacy of the anti-IL-6 rece ...... yelitis optica: a pilot study.

@nl

P1433

Q37725870-CB2BC550-4773-4C68-A91F-A621D6459922

P1476

Q37725870-EF2303EA-7F76-45F3-AC62-FBD5AA3A5B41

P2093

Q37725870-03E94727-01B7-4A7E-A0E0-9191D03DC997

Q37725870-28C73643-DA9A-4BFB-A589-D360632DD621

Q37725870-394BA211-EF5F-4E8E-A2D5-1DD7198C04FE

Q37725870-3A653F66-861D-4647-A34F-629D9FB592AA

Q37725870-A68216E1-1B47-44A4-BBA1-2C96EEB5C518

Q37725870-B7687C72-8A84-4457-96DC-86E0CA6C41D3

Q37725870-CD269ED3-12CD-4193-813C-90129EEF15DC

Q37725870-E084E1CB-F092-487D-B295-7C084A700EBC

P2860

Q37725870-229E4B2D-465C-4262-BBE5-C54D3CB5BC4C

Q37725870-35790261-89A0-4524-B215-C2505806FBB2

Q37725870-46081CE4-4861-441A-B0B1-B55FB237D379

Q37725870-77C6E84B-E04A-478A-8A89-3EF0C6112419

Q37725870-7D293133-6BB9-4974-ACA9-584764289F52

Q37725870-B4058641-E773-4123-B676-42C81EEC5687

Q37725870-C8859923-87AD-43CE-B600-2E27EF049F07

Q37725870-D63A9BD3-4A16-4A6B-BABB-47AD052BB5CA

Q37725870-E29E1FD0-9B45-4729-A8C1-0644F341828B

Q37725870-FC9869D4-E25A-492C-9E54-3677357D5EEE

P304

Q37725870-79747EFF-542C-4C0F-ACD0-5B51AE79A3D7

P31

Q37725870-C704B980-B152-4767-B87B-86407C660EE6

P356

Q37725870-E18BA311-1B6D-4878-BA27-FF97C7C37434

P407

Q37725870-6C08D139-01A4-4623-ACEC-659A9A1AF873

P433

Q37725870-31708A49-20F4-4254-B4B3-2F153EF9F9D3

P478

Q37725870-3291BA9F-BAD1-47EE-8357-156CD8E31D62

P50

Q37725870-F4815F52-D0E2-4EBF-89A5-E4D2DD48D261

P577

Q37725870-62C22140-E108-41A2-BD0B-24EC193652AC

P698

Q37725870-4282870F-0364-4059-82DB-7DD99179B31A

P921

Q37725870-DF3B55BF-6886-4AAA-B050-B63583F04AB3

P932

Q37725870-8D926C07-AB55-4235-A8E6-A1F95A9993EF

P356

WNL.0000000000000317

P1433

P1476

Efficacy of the anti-IL-6 rece ...... yelitis optica: a pilot study.

@en

P2093

Katsuichi Miyamoto

http://www.w3.org/2001/XMLSchema#string

Manabu Araki

http://www.w3.org/2001/XMLSchema#string

Miho Murata

http://www.w3.org/2001/XMLSchema#string

Sachiko Miyake

http://www.w3.org/2001/XMLSchema#string

Takako Matsuoka

http://www.w3.org/2001/XMLSchema#string

Takashi Yamamura

http://www.w3.org/2001/XMLSchema#string

Tomoko Okamoto

http://www.w3.org/2001/XMLSchema#string

Toshimasa Aranami

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy

Treatment of neuromyelitis optica: current debate.

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

Association of neuromyelitis optica with severe and intractable pain.

The role of glia and the immune system in the development and maintenance of neuropathic pain.

AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance.

Therapeutic targeting of the interleukin-6 receptor.

Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study.

A key role for gp130 expressed on peripheral sensory nerves in pathological pain.

P304

1302-1306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000000317

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P50

Susumu Kusunoki

P577

2014-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24634453

http://www.w3.org/2001/XMLSchema#string

P921

P932

4001188

http://www.w3.org/2001/XMLSchema#string